The Field. For Purposes of this Agreement, the “Field” shall include products other than the Subject Product and which are:

Field Examinations. [[Organization A:Organization]] shall pay to [[Organization B:Organization]] promptly at the conclusion of any collateral evaluation performed by or for the benefit of [[Organization B:Organization]] (namely any field examination, collateral analysis or other business analysis, the need for which is to be determined by [[Organization B:Organization]] and which evaluation is undertaken by [[Organization B:Organization]] or for [[Organization B:Organization]]'s benefit) a collateral evaluation fee in an amount equal to $1,250 (or such other amount customarily charged by [[Organization B:Organization]] to its customers) per day for each person employed to perform such evaluation, plus a per examination manager review fee (whether such examination is performed by [[Organization B:Organization]]'s employees or by a third party retained by [[Organization B:Organization]]) in the amount of $1,300 (or such other amount customarily charged by [[Organization B:Organization]] to its customers), plus all costs and disbursements incurred by [[Organization B:Organization]] in the performance of such examination or analysis, and further provided that if third parties are retained to perform such collateral evaluations, either at the request of another [[Organization C:Organization]] or for extenuating reasons determined by [[Organization B:Organization]] in its Permitted Discretion, then such fees charged by such third parties plus all costs and disbursements incurred by such third party, shall be the responsibility of [[Organization A:Organization]] and shall not be subject to the foregoing limits. So long as no Event of Default exists, [[Organization A:Organization]] shall only be obligated to pay or reimburse [[Organization B:Organization]] for up to three (3) field examinations in any calendar year.

Field Examination. [[Organization B:Organization]] shall have received satisfactory results from a pre-funding, asset-based field examination, to be completed prior to the date hereof, upon which [[Organization B:Organization]] is entitled to rely, conducted by examiners satisfactory to [[Organization B:Organization]];

Field Examination. The Administrative Agent or its designee shall have conducted a field examination of the Borrowers’ Accounts, Inventory and related working capital matters and of the Borrowers’ related data processing and other systems, the results of which shall be satisfactory to the Administrative Agent in its sole discretion.

“LICENSED FIELD” means all uses and applications.

a non-exclusive license, with the right to grant sublicenses in accordance with Section 2.2, to use UroGen’s Licensed Marks solely to the extent Allergan is required to use any of the Licensed Marks by Applicable Law to # research, develop, have developed, make, have made, use or import the RTGel Components in the Field in the Territory solely to make Licensed Products in the Field in the Territory and # Exploit the Licensed Products in the Field in the Territory.

Develop, Commercialize, make, have made, use, sell, have sold, offer for sale, import the Licensed Product in the Licensed Field throughout the Licensed Territory during the Term.

Licensed Trademarks. If Licensee elects to use any Licensed Trademark in connection with any Licensed Product, Licensee shall so notify Axsome in writing and Axsome shall provide to Licensee any trademark usage guidelines that Axsome may reasonably specify with respect to such Licensed Trademark. Licensee shall comply with and shall cause its Affiliates and Sublicensees to comply with such trademark usage guidelines in respect of any use of such Licensed Trademark.

Licensed Territory. SGI may perform Commercialization activities through one or more subcontractors without the prior written consent of Unum; provided that # SGI remains responsible for the work allocated to, and payment to, such subcontractors to the same extent it would if it had done such work itself; # the subcontractor undertakes in writing commercially reasonable obligations of confidentiality and non-use regarding Confidential Information that are substantially the same as those undertaken by the Parties with respect to Confidential Information pursuant to Article 15 hereof; and # the subcontractor undertakes in writing to assign or exclusively license back (with the right to sublicense) to SGI all intellectual property with respect to Products developed in the course of performing any such work .

Manufacturing Responsibility. Licensee will be responsible for the manufacturing of the Licensed Compound and Licensed Product for use by Licensee, its Affiliates, and its sublicensees in the Field in the Territory.

Licensee or its Affiliates shall hold all Marketing Authorizations for Licensed Product in the Territory in the Field.

Generally. Licensee shall use Diligent Efforts to Develop and Commercialize the Licensed Product in the Field in the Territory.

“Field” shall mean the use of the Licensed Compound or the Licensed Product for all therapeutic purposes in humans including but not limited to the treatment and prevention of any disease, disorder or condition.

Licensee shall oversee, monitor and coordinate all regulatory actions, communications and filings with, and submissions to, the FDA and other regulatory authorities in the Field in the Territory with respect to Licensed Product.

Licensee shall provide, disclose and transfer to Axsome all data obtained or collected solely to the extent such data or information relates to the Development or Commercialization of Licensed Products and is necessary to permit Axsome or Axsome’s designee to continue to Develop and Commercialize Licensed Products in the Field in the Territory;

Licensee shall transfer and assign to Axsome all Regulatory Approvals and other regulatory filings relating to any Licensed Product and to the extent that any such Regulatory Approval or other regulatory filing is necessary to permit Axsome to continue to Develop or Commercialize such Licensed Product in the Field in the Territory;

“DRL Licensed IP” means the IP and Know-How that DRL Controls on the Effective Date or during the Term that is necessary or reasonably useful to Develop, Commercialize, manufacture and otherwise exploit the Product and the Final Product in the Field. For clarity, the DRL Licensed IP shall include the Technical Package.

Overview. As of the Effective Date, Licensee shall be solely responsible for the Development and Commercialization, including all costs thereof, of the Licensed Product in the Field in the Territory. Licensee shall perform all of its Development activities in accordance with any IND for the Licensed Product and with all applicable laws, rules and regulations.

an exclusive (including with regard to ​ and its Affiliates except as provided in Section 5.7) license with respect to an anti-IL6R Nanobody, with the right to grant sublicenses in accordance with Section 5.4, under the ​ Nanobody Patents, solely to Exploit the Licensed Compound and Licensed Products in the Field in the Territory;